Amniotic membrane as a scaffold for melanocyte transplantation in patients with stable vitiligo

Pedro Redondo, Ana Giménez de Azcarate, Laura Marqués, María García-Guzman, Enrique Andreu, Felipe Prósper, Pedro Redondo, Ana Giménez de Azcarate, Laura Marqués, María García-Guzman, Enrique Andreu, Felipe Prósper

Abstract

Vitiligo is an acquired skin disease that significantly impacts the quality of life of patients. Medical treatment of vitiligo includes the use of melanocyte transplant, but the results are variable. We have treated 4 patients with either focal or generalized stable vitiligo using a graft of autologous melanocytes' culture on a denuded amniotic membrane (AM). A culture biopsy was obtained in every patient and grown in melanocytes' media for 10-14 days after which cells were transferred to a denuded AM and transplanted into the achromic lesions. Patients were followed for up to 6 months using clinical assessment of achromic lesions. Treated areas ranged between 4 cm(2) and 210.6 cm(2). Response to treatment was excellent in all patients with 90-95% repigmentation success rate. Our results demonstrate that transplantation of autologous melanocytes cultured on AM is a new, simple, and effective treatment for stable vitiligo.

Figures

Figure 1
Figure 1
Piece of amniotic membrane (a); immunohistochemistry for HMB-45 applied to cells cultured on slide. A large number of melanocytes can be observed (b); micrograph of cross-sectioned AM stained with HMB-45 after cell culture (c). Original magnification: (b, c) X100.
Figure 2
Figure 2
Patient 1. Preoperatively (a); the achromic epidermis was removed using CO2 laser, and AM carrying cultured melanocytes on the basement membrane surface was applied on the denuded area with one layer of Vaseline gauze. The amniotic membranes were fixed with steri-strips and covered with dry gauze and adhesive tape (b); postoperative photography (>90% repigmentation at 16 weeks) (c).
Figure 3
Figure 3
Patient 3. Preoperatively (a), desepidermized lesion after treatment with CO2 laser (b), and postoperative photographs (>90% repigmentation at 16 weeks) (c).

References

    1. Castanet J, Ortonne JP. Pathophysiology of vitiligo. Clinics in Dermatology. 1997;15(6):845–851.
    1. Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity. 2001;34(1):65–77.
    1. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Research. 2003;16(2):90–100.
    1. Hautmann G, Panconesi E. Vitiligo: a psychologically influenced and influencing disease (review) Clinics in Dermatology. 1997;15(6):879–890.
    1. Van Geel N, Ongenae K, Naeyaert JM. Surgical techniques for vitiligo: a review. Dermatology. 2001;202(2):162–166.
    1. Njoo MD, Westerhof W, Bos JD, Bossuyt PMM. A systemic review of autologous transplantation methods in vitiligo. Archives of Dermatology. 1998;134(12):1543–1549.
    1. Falabella R. Surgical therapies for vitiligo (review) Clinics in Dermatology. 1997;15(6):927–939.
    1. Andreassi L, Pianigiani E, Andreassi A, Taddeucci P, Biagioli M. A new model of epidermal culture for the surgical treatment of vitiligo. International Journal of Dermatology. 1998;37(8):595–598.
    1. Olsson MJ, Juhlin L. Transplantation of melanocytes in vitiligo. British Journal of Dermatology. 1995;132(4):587–591.
    1. Davis JW. Skin transplantation with a review of 550 cases at the Johns Hopkins Hospital. Johns Hopkins Medical Journal. 1910;15:307–312.
    1. Lin SD, Lai CS, Hou MF, Yang CC. Amnion overlay meshed skin autograft. Burns, Including Thermal Injury. 1985;11(5):374–378.
    1. Ward DJ, Bennett JP, Burgos H, Fabre J. The healing of chronic venous leg ulcers with prepared human amnion. British Journal of Plastic Surgery. 1989;42(4):463–467.
    1. John T, Foulks GN, John ME, Cheng K, Hu D. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology. 2002;109(2):351–360.
    1. Martinez ME, Reyes ML, Ramos T, et al. Clinical application of amniotic membranas on patient with epidermolysis bullosa. Annals of Transplantation. 1999;4:68–73.
    1. Subrahmanyam M. Amniotic membrane as a cover for microskin grafts. British Journal of Plastic Surgery. 1995;48(7):477–478.
    1. Kucan JO, Robson MC, Parsons RW. Amniotic membranes as dressings following facial dermabrasion. Annals of Plastic Surgery. 1982;8(6):523–527.
    1. Kim JC, Tseng SC. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. Cornea. 1995;14(5):473–484.
    1. Ishino Y, Sano Y, Nakamura T, et al. Amniotic membrane as a carrier for cultivated human corneal endothelial cell transplantation. Investigative Ophthalmology & Visual Science. 2004;45:800–806.
    1. Lee SH, Tseng SCG. Amniotic membrane transplantation for persistent epithelial defects with ulceration. American Journal of Ophthalmology. 1997;123(3):303–312.
    1. Solomon A, Rosenblatt M, Monroy D, Ji Z, Pflugfelder SC, Tseng SCG. Suppression of interleukin-1a and interleukin-1b in human limbal epithelial cells cultured on the amniotic membrane stromal matrix. British Journal of Ophthalmology. 2001;85(4):444–449.
    1. Tseng SC, Li DQ, Ma X. Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. Journal of Cellular Physiology. 1999;179(3):325–335.
    1. Talmi YP, Sigler L, Inge E, Finkelstein Y, Zohar Y. Antibacterial properties of human amniotic membranes. Placenta. 1991;12(3):285–288.
    1. Kruse FE, Joussen AM, Rohrschneider K, et al. Cryopreserved human amniotic membrane for ocular surface reconstruction. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2000;238(1):68–75.
    1. Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. British Journal of Dermatology. 2008;159(5):1051–1076.
    1. Gauthier Y, Surleve-Bazeille JE. Autologous grafting with non-cultured melanocytes: a simplified method for treatment of depigmented lesions. Journal of the American Academy of Dermatology. 1992;26(2):191–194.
    1. Sahni K, Parsad D, Kanwar AJ. Noncultured epidermal suspension transplantation for the treatment of stable vitiligo in children and adolescents. Clinical and Experimental Dermatology. 2011;36(6):607–612.
    1. Redondo P, Del Olmo J, García-Guzman M, Guembe L, Prósper F. Repigmentation of vitiligo by transplantation of autologous melanocyte cells cultured on amniotic membrane. British Journal of Dermatology. 2008;158(5):1168–1171.
    1. Fukuda K, Chikama TI, Nakamura M, Nishida T. Differential distribution of subchains of the basement membrane components type IV collagen and laminin among the amniotic membrane, cornea, and conjunctiva. Cornea. 1999;18(1):73–79.
    1. Meller D, Pires RTF, Tseng SCG. Ex vivo preservation and expansion of human limbal epithelial stem cells on amniotic membrane cultures. British Journal of Ophthalmology. 2002;86(4):463–471.
    1. Van Geel N, Ongenae K, De Mil M, Vander Haeghen Y, Vervaet C, Naeyaert JM. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. Archives of Dermatology. 2004;140(10):1203–1208.
    1. Olsson MJ, Juhlin L. Long-term follow-up of leucoderma patients treated with trasplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension. British Journal of Dermatology. 2002;147(5):893–904.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다